DX 0385Alternative Names: DX-0385
Latest Information Update: 19 Jul 2016
At a glance
- Originator DermaXon
- Class Antiacnes
- Mechanism of Action Retinoic acid metabolism modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acne
Most Recent Events
- 19 Jul 2016 Preclinical trials in Acne in USA (unspecified route)